Sonora Medical Unit of Misonix Recognized by Medical Imaging Magazine Among Industry's Brightest in Readers' Choice Awards.

FARMINGDALE, N.Y. -- Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that its majority-owned Sonora Medical Systems, Inc. subsidiary was recognized among the industry's brightest in Medical Imaging Magazine's 2006 Readers' Choice Awards. In the 11th annual Medical Imaging Readers' Choice Awards, the leading trade magazine's readers voiced their opinions on who is providing unbeatable equipment, software, and services to the health care industry. Sonora ranked among the highest within the Dealer/Distributor and Remanufacturer/Rebuilder group.

Now in its 11th year, the Medical Imaging Readers' Choice Awards, asks readers to vote on the top medical-imaging vendors, basing selections on price, service, quality, training, and integration. Medical Imaging Magazine e-mailed ballots to more than 10,500 readers, and votes were taken between September 25 and October 23. For all vendors that were identified in the returned ballots, being named among the best by Medical Imaging's readers means that they are netting accolades from their customers and peers, and setting high standards in today's increasingly crowded health care market.

"We are proud of the entire team at Sonora Medical, which has been recognized for the third straight year as a leading vendor in Medical Imaging Magazine's survey," said Michael A. McManus, Jr., President and Chief Executive Officer of the Company. "The praise from customers and business partners alike reflect the strong leadership and extraordinary product line at Sonora. This is an important segment of Misonix as it enables us to participate in the broader imaging technology market that is projected to increase from $13 billion in the United States in 2005 to nearly $17 billion in 2008."

Since its founding in 1996, Sonora has worked to meet the demanding and varying needs of clinicians, service companies, OEMs, and independent dealers by increasing ultrasound and MRI quality and clinical efficacy. Sonora has several attributes that contributed toward its impressive placement in Medical Imaging awards: a large number of very experienced and knowledgeable employees who are dedicated to making a difference; a quality system that is certified to ISO 9001 and ISO 13485, which makes the company unique among independent (non-OEM) ultrasound vendors; and ongoing efforts to be a company that is easy to work with, that listens to its customers, and promotes innovative thinking.

As evidence of its industry leadership, Sonora has developed and commercialized the first ever electro-acoustic ultrasound test device, the FirstCall, opening an entirely new market segment in diagnostic ultrasound. Since its market inception just five years ago, the FirstCall has received five US Patents with three additional patents pending. Along with the FirstCall, Sonora recently introduced another breakthrough product, the Nickel, a hand-held device that directly tests all the major modes of operation of any commercial ultrasound system.

Sonora's products and services are designed to extend the life of medical imaging equipment, improve their efficacy, and reduce the total cost of ownership. By consistently evaluating its processes and procedures, the company continues to identify and implement improvements that lead to higher customer value and satisfaction.

About Medical Imaging Magazine:

Medical Imaging is a leading monthly news and business magazine for radiology and imaging professionals who are involved in selecting, managing, and supporting technology that is used in the medical-imaging department of a healthcare provider facility.

Medical Imaging subscribers include radiologists, hospital and radiology administrators, PACS/RIS administrators, technology managers, IT networking managers, technicians, medical physicists, radiation oncologists, and clinical staff. In addition to those at healthcare facilities, the publication reaches subscribers at manufacturing companies, OEMs, dealers, distributors, and resellers.

About Sonora Medical Systems, Inc.:

Sonora Medical Systems is an ISO-9000 certified and FDA registered provider of high quality products and services to the diagnostic ultrasound and MRI markets. Its products and services are marketed on a direct basis to healthcare providers, dealers and service organizations in North America, and both directly and through distribution partners in non-U.S. markets. Customers include large and small hospitals, stand-alone imaging centers, clinics, Independent Service Organizations (ISOs) and Original Equipment Manufacturers (OEMs). Located in Longmont, Colorado, Sonora is a subsidiary of Misonix, Inc. (NASDAQ: MSON). Additional information on Sonora is available at its Web site at www.4sonora.com.

About Misonix:

Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

1. Frost and Sullivan/Medical Imaging Magazine.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.